Jan 10, 2023 / 11:45PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside chat with Eli Lilly. Lilly has obviously had a tremendous few years here and very much looking forward to the discussion today. So from Lilly, we have Anat Ashkenazi, the company's CFO; as well as Dan Skovronsky, the Chief Scientific Officer. So Anat, and Dan, thanks for joining today.
So I guess just to maybe open up with some opening comments about -- as we think about 2023 and Lilly's positioning heading into this year, maybe just kind of set the stage of how you're thinking about the business, and then we can obviously jump into a lot of different topics.
Anat Ashkenazi - Eli Lilly and Company - Senior VP & CFO
Sure. Thanks. First, thanks, everyone, for joining us and having an interest in hearing more about the Lilly story. So we're closing out 2022. We've shared our results through the third quarter and shortly in a few weeks, we'll share the full year
Eli Lilly and Co at JPMorgan Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers